\-\ Texto\\:\\ \ \(0\)\
\-\ normal\\ ast\\,\\ alt\\,\\ alk\\ phos\\,\\ and\\ total\\ bilirubin\\.\ \(0\)\
\-\ no\\ treatment\\ or\\ followup\\ is\\ necessary\\ in\\ this\\ case\\.\ \(0\)\
\-\ discontinuous\\ peripheral\\ pooling\\ of\\ contrast\\ enhancement\\ in\\ the\\ arterial\\ phase\\ with\\ progressive\\ filling\\ seen\\ in\\ the\\ portal\\ venous\\ phase\\ and\\ prolonged\\ enhancement\\ of\\ the\\ lesion\\ in\\ delayed\\ images\\ on\\ a\\ three\\ phase\\ enhanced\\ liver\\ ct\\.\ \(0\)\
\-\ liver\\ hemangioma\ \(2\)\
\-\ ddx\\ of\\ hypodense\\ liver\\ lesion\\:\ \(0\)\
\-\ \\â\\€\\¢\\	cavernous\\ hemangioma\ \(0\)\
\-\ \\â\\€\\¢\\	metastatic\\ disease\\ \ \(0\)\
\-\ \\â\\€\\¢\\	hcc\ \(0\)\
\-\ \\â\\€\\¢\\	focal\\ nodular\\ hyperplasia\ \(0\)\
\-\ \\â\\€\\¢\\	hepatic\\ cyst\ \(0\)\
\-\ \\â\\€\\¢\\	fibrolamellar\\ carcinoma\ \(0\)\
\-\ \\â\\€\\¢\\	lymphoma\ \(0\)\
\-\ \\â\\€\\¢\\	hepatic\\ adenoma\ \(0\)\
\-\ 38\\ y\\/o\\ woman\\ to\\ evaluate\\ liver\\ lesion\\.\ \(1\)\
\-\ note\\:\\ \\ these\\ are\\ dynamic\\ enhanced\\ images\\ that\\ confirm\\ benign\\ hemangioma\\.\\ \\ the\\ discontinuous\\ peripheral\\ pooling\\ of\\ contrast\\ enhancement\\ in\\ the\\ arterial\\ phase\\ \\-\\ followed\\ by\\ progressive\\ filling\\ seen\\ in\\ the\\ portal\\ venous\\ phase\\ \\-\\ with\\ prolonged\\ enhancement\\ of\\ the\\ lesion\\ on\\ the\\ delayed\\ images\\ \\-\\ is\\ classic\\ for\\ hemangioma\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ phase\\:\\ 0\\.3875960131858974\ \(0\)\
\-\ hemangioma\\:\\ 0\\.3048165819369654\ \(0\)\
\-\ liver\\:\\ 0\\.24997859678614032\ \(0\)\
\-\ discontinuous\\:\\ 0\\.24572108854208444\ \(0\)\
\-\ pooling\\:\\ 0\\.2279463475615879\ \(0\)\
\-\ enhancement\\:\\ 0\\.20857304808112007\ \(0\)\
\-\ prolonged\\:\\ 0\\.17549385172433013\ \(0\)\
\-\ lesion\\:\\ 0\\.17372755962735387\ \(0\)\
\-\ portal\\:\\ 0\\.1733896121844554\ \(0\)\
\-\ arterial\\:\\ 0\\.14920937330384176\ \(0\)\
\-\ the\\:\\ 0\\.1446113250776494\ \(0\)\
\-\ hepatic\\:\\ 0\\.14428601866008514\ \(0\)\
\-\ delayed\\:\\ 0\\.14178128099296394\ \(0\)\
\-\ filling\\:\\ 0\\.1403105367414638\ \(0\)\
\-\ progressive\\:\\ 0\\.13876768859686625\ \(0\)\
\-\ enhanced\\:\\ 0\\.13795668962345814\ \(0\)\
\-\ in\\:\\ 0\\.1352183145072376\ \(0\)\
\-\ peripheral\\:\\ 0\\.12956183550177827\ \(0\)\
\-\ venous\\:\\ 0\\.12935757498526104\ \(0\)\
\-\ images\\:\\ 0\\.12571469604465307\ \(0\)\
\-\ fibrolamellar\\:\\ 0\\.11185253497124363\ \(0\)\
\-\ hcc\\:\\ 0\\.10476496004647058\ \(0\)\
\-\ dynamic\\:\\ 0\\.10240787219782888\ \(0\)\
\-\ bilirubin\\:\\ 0\\.09730073820905852\ \(0\)\
\-\ alk\\:\\ 0\\.09473960643461299\ \(0\)\
\-\ phos\\:\\ 0\\.093756950746672\ \(0\)\
\-\ of\\:\\ 0\\.088642409624283\ \(0\)\
\-\ contrast\\:\\ 0\\.08803374783057895\ \(0\)\
\-\ hypodense\\:\\ 0\\.08796598037550121\ \(0\)\
\-\ alt\\:\\ 0\\.08710732799798354\ \(0\)\
\-\ ast\\:\\ 0\\.0868997276506159\ \(0\)\
\-\ ddx\\:\\ 0\\.08609544437935594\ \(0\)\
\-\ seen\\:\\ 0\\.08530009733548455\ \(0\)\
\-\ confirm\\:\\ 0\\.08477908884106558\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.08259091824828049\ \(0\)\
\-\ 38\\:\\ 0\\.0803918535982317\ \(0\)\
\-\ followup\\:\\ 0\\.07998635411152766\ \(0\)\
\-\ cavernous\\:\\ 0\\.0785822819780145\ \(0\)\
\-\ necessary\\:\\ 0\\.07578892705068772\ \(0\)\
\-\ total\\:\\ 0\\.0742287827020397\ \(0\)\
\-\ adenoma\\:\\ 0\\.07222466092598338\ \(0\)\
\-\ nodular\\:\\ 0\\.07214300933004257\ \(0\)\
\-\ evaluate\\:\\ 0\\.07044534402282598\ \(0\)\
\-\ note\\:\\ 0\\.06819714468468831\ \(0\)\
\-\ classic\\:\\ 0\\.06775858268221592\ \(0\)\
\-\ benign\\:\\ 0\\.06223068965035417\ \(0\)\
\-\ followed\\:\\ 0\\.061175773352837866\ \(0\)\
\-\ three\\:\\ 0\\.060812528028624066\ \(0\)\
\-\ on\\:\\ 0\\.054720765954454346\ \(0\)\
\-\ focal\\:\\ 0\\.054188126884644194\ \(0\)\
\-\ carcinoma\\:\\ 0\\.054188126884644194\ \(0\)\
\-\ lymphoma\\:\\ 0\\.053953232209982556\ \(0\)\
\-\ cyst\\:\\ 0\\.0522592683828962\ \(0\)\
\-\ these\\:\\ 0\\.05115737031844311\ \(0\)\
\-\ metastatic\\:\\ 0\\.049685260092602\ \(0\)\
\-\ is\\:\\ 0\\.04961854914286042\ \(0\)\
\-\ woman\\:\\ 0\\.047180685660127675\ \(0\)\
\-\ case\\:\\ 0\\.04551250887053188\ \(0\)\
\-\ treatment\\:\\ 0\\.04315384594870242\ \(0\)\
\-\ that\\:\\ 0\\.03931359386798047\ \(0\)\
\-\ by\\:\\ 0\\.038470679153845694\ \(0\)\
\-\ disease\\:\\ 0\\.038027364435363906\ \(0\)\
\-\ and\\:\\ 0\\.037439515568262784\ \(0\)\
\-\ normal\\:\\ 0\\.036988165625921665\ \(0\)\
\-\ with\\:\\ 0\\.03547814937716448\ \(0\)\
\-\ ct\\:\\ 0\\.034489280402892106\ \(0\)\
\-\ are\\:\\ 0\\.034375599169965666\ \(0\)\
\-\ or\\:\\ 0\\.03151539435528077\ \(0\)\
\-\ this\\:\\ 0\\.03112909267815663\ \(0\)\
\-\ no\\:\\ 0\\.029459534943860586\ \(0\)\
\-\ for\\:\\ 0\\.02745778408245747\ \(0\)\
\-\ to\\:\\ 0\\.02264785846365907\ \(0\)\
